Endoskopische Therapie bei Adipositas und Diabetes mellitus

Adipositas und Diabetes sind mit einer erhöhten Mortalität und Morbidität assoziiert. Nach Versagen einer konservativen Therapie (medikamentös, Lifestyleänderung) ist bei ausgewählten Patienten eine bariatrische Behandlung indiziert. Endoskopische Techniken stellen hier etablierte Behandlungsoptionen für Übergewichtige dar, die sich nicht für eine metabolische Chirurgie eignen oder nicht bereit sind, sich einer Operation zu unterziehen. Dieser Beitrag gibt einen Überblick über derzeit verfügbare endoskopische Techniken zur Gewichtsreduktion und Verbesserung einer diabetischen Stoffwechsellage.

Publikationsverlauf

Artikel online veröffentlicht:
11. Februar 2025

• Literatur

• 1 Kelly T, Yang W, Chen CS. et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008; 32: 1431-1437
• 2 Guh DP, Zhang W, Bansback N. et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88
• 3 Fontaine KR, Redden DT, Wang C. et al. Years of life lost due to obesity. JAMA 2003; 289: 187-193
• 4 Heidemann C, Scheidt-Nave C. Prävalenz, Inzidenz und Mortalität von Diabetes mellitus bei Erwachsenen in Deutschland – Bestandsaufnahme zur Diabetes-Surveillance. J Health Monit 2017; 3
• 5 Sarwar N, Gao P, Seshasai SR. et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-2222
• 6 Reitzle L, Schmidt C, Du Y. et al. Einschätzungen zur Prävalenz mikrovaskulärer Folgeerkrankungen bei Diabetes mellitus in Deutschland. Analyse von Versichertendaten aller gesetzlichen Krankenkassen für die Jahre 2012 und 2013. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 1219-1230
• 7 Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic Bariatric and Metabolic Therapies: New and Emerging Technologies. Gastroenterology 2017; 152: 1791-1801 2017.01.044
• 8 AWMF. S3-Leitlinie Chirurgie der Adipositas und metabolischer Erkrankungen. AWMF-Register-Nr. 088-001; 2018. Im Internet: https://www.awmf.org/uploads/tx_szleitlinien/088-001l_S3_Chirurgie-Adipositas-metabolische-Erkrankugen_2018-02.pdf; Stand: 13.10.2022
• 9 Abu Dayyeh BK, Kumar N, Edmundowicz SA. et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015; 82: 425-438. e425
• 10 Gómez V, Woodman G, Abu Dayyeh BK. Delayed gastric emptying as a proposed mechanism of action during intragastric balloon therapy: Results of a prospective study. Obesity (Silver Spring) 2016; 24: 1849-1853
• 11 Turkeltaub JA, Edmundowicz SA. Endoscopic Bariatric Therapies: Intragastric Balloons, Tissue Apposition, and Aspiration Therapy. Curr Treat Options Gastroenterol 2019; 17: 187-201
• 12 Jamal MH, Al-Kanawati N, ElAbd R. et al. A Study Examining the Orbera365 Intragastric Balloon Safety and Effects on Weight Loss. Obes Surg 2021; 31: 5342-5347
• 13 Popov VB, Ou A, Schulman AR. et al. The Impact of Intragastric Balloons on Obesity-Related Co-Morbidities: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2017; 112: 429-439
• 14 Tate CM, Geliebter A. Intragastric Balloon Treatment for Obesity: Review of Recent Studies. Adv Ther 2017; 34: 1859-1875
• 15 Loo JH, Lim YH, Seah HL. et al. Intragastric Balloon as Bridging Therapy Prior to Bariatric Surgery for Patients with Severe Obesity (BMI≥50 kg/m(2)): a Systematic Review and Metaanalysis. Obes Surg 2022; 32: 489-502
• 16 Yorke E, Switzer NJ, Reso A. et al. Intragastric Balloon for Management of Severe Obesity: a Systematic Review. Obes Surg 2016; 26: 2248-2254
• 17 Tate CM, Geliebter A. Intragastric Balloon Treatment for Obesity: FDA Safety Updates. Adv Ther 2018; 35: 1-4
• 18 Chan DL, Cruz JR, Mui WL. et al. Outcomes with Intra-gastric Balloon Therapy in BMI<35 Non-morbid Obesity: 10-Year Follow-Up Study of an RCT. Obes Surg 2021; 31: 781-786
• 19 de Moura EG, Lopes GS, Martins BC. et al. Effects of Duodenal-Jejunal Bypass Liner (EndoBarrier) on Gastric Emptying in Obese and Type 2 Diabetic Patients. Obes Surg 2015; 25: 1618-1625
• 20 Sandler BJ, Biertho L, Anvari M. et al. Totally endoscopic implant to effect a gastric bypass: 12-month safety and efficacy outcomes. Surg Endosc 2018; 32: 4436-4442
• 21 Abu Dayyeh BK, Acosta A, Camilleri M. et al. Endoscopic Sleeve Gastroplasty Alters Gastric Physiology and Induces Loss of Body Weight in Obese Individuals. Clin Gastroenterol Hepatol 2017; 15: 37-43.e31
• 22 Li P, Ma B, Gong S. et al. Efficacy and safety of endoscopic sleeve gastroplasty for obesity patients: a meta-analysis. Surg Endosc 2020; 34: 1253-1260
• 23 Hedjoudje A, Abu Dayyeh BK, Cheskin LJ. et al. Efficacy and Safety of Endoscopic Sleeve Gastroplasty: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol 2020; 18: 1043-1053.e1044
• 24 Sharaiha RZ, Kumta NA, Saumoy M. et al. Endoscopic Sleeve Gastroplasty Significantly Reduces Body Mass Index and Metabolic Complications in Obese Patients. Clin Gastroenterol Hepatol 2017; 15: 504-510
• 25 Fayad L, Adam A, Schweitzer M. et al. Endoscopic sleeve gastroplasty versus laparoscopic sleeve gastrectomy: a case-matched study. Gastrointest Endosc 2019; 89: 782-788
• 26 López-Nava G, Bautista-Castaño I, Jimenez A. et al. The Primary Obesity Surgery Endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis 2015; 11: 861-865
• 27 Sullivan S, Swain JM, Woodman G. et al. Randomized shamcontrolled trial evaluating efficacy and safety of endoscopic gastric plication for primary obesity: The ESSENTIAL trial. Obesity (Silver Spring) 2017; 25: 294-301
• 28 Hollenbach M, Selig L, Lellwitz S. et al. Endoscopic full-thickness transoral outlet reduction with semicircumferential endoscopic submucosal dissection. Endoscopy 2019; 51: 684-688
• 29 Sullivan S, Stein R, Jonnalagadda S. et al. Aspiration therapy leads to weight loss in obese subjects: a pilot study. Gastroenterology 2013; 145: 1245-1252.e1-5
• 30 Nyström M, Machytka E, Norén E. et al. Aspiration Therapy As a Tool to Treat Obesity: 1- to 4-Year Results in a 201-Patient Multi-Center Post-Market European Registry Study. Obes Surg 2018; 28: 1860-1868
• 31 Thompson CC, Abu Dayyeh BK, Kushner R. et al. Percutaneous Gastrostomy Device for the Treatment of Class II and Class III Obesity: Results of a Randomized Controlled Trial. Am J Gastroenterol 2017; 112: 447-457
• 32 van Baar ACG, Haidry R, Rodriguez Grunert L. et al. Duodenal mucosal resurfacing: Multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitus. Endosc Int Open 2020; 8: E1683-E1689
• 33 de Oliveira GHP, de Moura DTH, Funari MP. et al. Metabolic Effects of Endoscopic Duodenal Mucosal Resurfacing: a Systematic Review and Meta-analysis. Obes Surg 2021; 31: 1304-1312
• 34 van Baar ACG, Holleman F, Crenier L. et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut 2020; 69: 295-303
• 35 Mingrone G, van Baar AC, Devière J. et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut 2022; 71: 254-264